文献速递血栓与止血

住院癌症患者静脉血栓栓塞症风险分层:Khorana评分预测院内症状性静脉血栓栓塞症

Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
PubMed 文献 · J Thromb Haemost · 2018-06-10

该多中心分析纳入2010年1月至6月三家学术医疗中心连续住院的成年癌症患者1398例,评估入院时Khorana评分对住院期间症状性静脉血栓栓塞症(VTE)的预测价值。VTE总发生率为2.9%(95%CI 2.0-3.8%),高危组5.4%、中危组3.2%、低危组1.4%;高危较低危的OR为3.9(95%CI 1.4-11.2)。

要点

  • Khorana评分可预测住院癌症患者院内症状性VTE的发生。
  • VTE总发生率2.9%(95%CI 2.0-3.8%),高危组5.4%、中危组3.2%、低危组1.4%。
  • 高危较低危患者发生VTE的OR为3.9(95%CI 1.4-11.2)。

核心结论

  • Khorana评分可预测因内科原因住院的癌症患者院内症状性VTE的发生,可能有助于制定住院期间抗凝血栓预防方案。

研究设计与样本

  • 对2010年1月至6月三家学术医疗中心连续住院的成年癌症患者进行多中心分析,共纳入1398例。

主要发现

  • 患者平均年龄62岁,男性占51.2%,平均BMI为25.9 kg m-2。
  • 住院最常见原因为化疗给药(22.3%),其次为疼痛控制与姑息治疗(21.4%)。
  • VTE总发生率为2.9%(95%CI 2.0-3.8%),高危组为5.4%(95%CI 1.9-8.9%)、中危组为3.2%(95%CI 2.0-4.4%)、低危组为1.4%(95%CI 0.3-2.6%)。
  • 高危患者较低危患者更易发生VTE(OR 3.9;95%CI 1.4-11.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The Khorana score is validated for risk of venous thromboembolism (VTE) in cancer outpatients. We conducted a multicenter analysis of medically hospitalized cancer patients. Patients with a higher Khorana score on admission were more likely to develop VTE. The Khorana score is predictive of in-hospital, symptomatic VTE development. SUMMARY: Introduction The Khorana score is a validated risk assessment score for estimating the risk of symptomatic venous thromboembolism (VTE) in outpatients with cancer. The objective of this study was to assess the Khorana score for predicting the development of VTE in cancer patients during hospital admission. Methods We conducted an analysis of consecutive, adult cancer patients hospitalized for medical reasons between January and June 2010 in three academic medical centers. Information on objectively diagnosed, symptomatic VTE during hospitalization, use of anticoagulant thromboprophylaxis (TP) and Khorana score variables at the time of admission was collected. Results A total of 1398 patients were included. Mean age was 62 years, 51.2% were male, and mean BMI was 25.9 kg m-2 . The most frequent reasons for hospitalization were chemotherapy administration (22.3%), followed by pain control and palliation (21.4%). The overall incidence of VTE was 2.9% (95% CI, 2.0-3.8%), occurring in 5.4% (95% CI, 1.9-8.9%) of the high-, 3.2% (95% CI, 2.0-4.4%) of the intermediate- and 1.4% (95% CI, 0.3-2.6%), of the low-risk groups. High-risk patients were more likely than low-risk patients to have VTE (OR, 3.9; 95% CI, 1.4-11.2). Conclusion The Khorana score is predictive of in-hospital, symptomatic VTE development in cancer patients who are hospitalized for medical reasons and may be a useful tool for tailoring inpatient anticoagulant thromboprophylaxis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 2018. PMID: 29733498. doi:10.1111/jth.14139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。